1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC). (September 2015) - Cortes, J.; Crown, J.; Awada, A.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Martinez-Janez, N.; Chan, S.; Steinberg, J.L.; Blaney, M.; Tudor, I.C.; Uppal, H.; et al.